832
Eaton, Lynn, 2003. Readers want transparency in link between doctors and drug firms. BMJ, 326, 1352.
833
Mayor, Susan, 2002. Researchers claim clinical trials are reported with misleading statistics. BMJ, 324, 1353.
834
JAMA, 2003, 389, 454–465, quoted by Hopkins Tanne, Janice, 2003. Industry is deeply involved in funding US research. BMJ, 326, 179.
835
Tonks, Alison, 2002. Authors of guidelines have strong links with drugs industry. BMJ, 324, 383.
836
Spurgeon, David, 2002. Doctors accept $50 a time to listen to drug representatives. BMJ, 324, 1113.
837
Gottlieb, Scott, 2003. A fifth of Americans contact their doctor as a result of direct to consumer drug advertising. BMJ, 325, 854.
838
BMJ, 2003. Drug companies want to inform patients. BMJ, 326, 1286.
839
Watson, Rory, 2003. EU health ministers reject proposal for limited direct to consumer advertising. BMJ, 326, 1284.
840
Watson, R., 2006. Cancer group denies company funding will influence its agenda. BMJ, 333, 874.
841
Mayor, Susan, 2002. GMC issues new guidance on clinical research. BMJ, 324, 384.
842
Marwick, Charles, 2002. US tackles drug company gifts to doctors. BMJ, 325, 795.
843
Mosconi, Paola, 2003. Declaration of competing interests is rare in Italian breast cancer associations. BMJ, 327, 344.
844
Herxheimer, A., 2003. Relationships between the pharmaceutical industry and patients' organisations. BMJ, 326, 1208–1210.
845
Hirst, J., 2003. Charities and patient groups should declare interests. BMJ, 326, 1211.
846
Clark, Jocalyn, 2003. A hot flush for Big Pharma. BMJ, 327, 400.
847
Writing Group for the Women's Health Initiative Investigators, 2002. Risks and benefi ts of estrogen plus progestin in healthy postmenopausal women. JAMA, 288, 321–333.
